Fiche du document
2021
- doi: 10.3389/fimmu.2021.701636
- issn: 1664-3224
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.3389/fimmu.2021.701636
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/34394096
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1664-3224
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_132C3057D9465
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Therapy Treatments for diseases Medical treatment Therapy Treatment of diseases Thymus-dependent lymphocytes Thymus-derived cells T lymphocytes Thymus-dependent cells Therapeutic immunologyCiter ce document
M. Arnaud et al., « The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients. », Serveur académique Lausannois, ID : 10.3389/fimmu.2021.701636
Métriques
Partage / Export
Résumé
Mutation-derived neoantigens are now established as attractive targets for cancer immunotherapy. The field of adoptive T cell transfer (ACT) therapy was significantly reshaped by tumor neoantigens and is now moving towards the genetic engineering of T cells with neoantigen-specific T cell receptors (TCRs). Yet, the identification of neoantigen-reactive TCRs remains challenging and the process needs to be adapted to clinical timelines. In addition, the state of recipient T cells for TCR transduction is critical and can affect TCR-ACT efficacy. Here we provide an overview of the main strategies for TCR-engineering, describe the selection and expansion of optimal carrier cells for TCR-ACT and discuss the next-generation methods for rapid identification of relevant TCR candidates for gene transfer therapy.